Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVC-203
- Development stage
- Phase 2
- Lead developer
- AvenCell Therapeutics
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**AVC-203** is an investigational, CRISPR-engineered, healthy-donor-derived allogeneic CD19/CD20 dual-targeting CAR-T cell therapy from AvenCell for relapsed or refractory B-cell malignancies. The off-the-shelf product is engineered to reduce graft-versus-host disease and host immune rejection, while its CAR recognizes B cells expressing CD19 and/or CD20. It also incorporates AvenCell's RevCAR switchable receptor architecture, intended to permit externally controlled activity and future expansion to additional tumor antigens through bridging proteins. AVC-203 is being evaluated in the Phase I/II QUADvance study, including cohorts in relapsed or refractory B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma. ([avencell.com](https://avencell.com/avencell-therapeutics-announces-first-patient-dosed-in-phase-i-quadvance-study-with-avc-203-a-novel-allogeneic-cd19-cd20-dual-targeting-car-t-investigational-therapy-for-the-treatment-of-relapsed-ref/))
- Other names
- Allo-QuadCAR01-TAllo-QuadCAR-01-TAllo-QuadCAR 01-T
02
Targets
Beyond the preview
Go deeper on AVC-203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVC-203.